Welcome to our dedicated page for Vyne Therapeutics news (Ticker: YARW), a resource for investors and traders seeking the latest updates and insights on Vyne Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vyne Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vyne Therapeutics's position in the market.
Yarrow Bioscience (Nasdaq: YARW) completed its merger with VYNE Therapeutics and closed previously announced private financings totaling approximately $200 million, which are expected to fund operations into 2028. The combined company will operate as Yarrow Bioscience and its common stock is expected to begin trading on the Nasdaq Capital Market on July 28, 2026 under ticker YARW.
Yarrow’s lead asset YB-101, a potential first-in-class anti-TSHR monoclonal antibody for Graves’ disease (GD) and thyroid eye disease (TED), has begun dosing in a randomized Phase 2a/2b GD trial after receiving FDA Fast Track Designation. Phase 2a data are expected in 2H 2027, with a Phase 2b dose-finding part anticipated to start in 1H 2028. Partner GenSci is running Phase 1 SAD/MAD trials in TED and GD in China; SAD TED data showed dose-dependent proof-of-mechanism and favorable safety, enabling MAD and Yarrow’s Phase 2a/2b trial. Following a 1-for-50 VYNE reverse stock split and merger, the combined company has about 2.8 million shares outstanding, or 33.6 million fully diluted, and a new CUSIP of 92941V407.